Takeda is buying Ariad Pharmaceuticals in a $5.2 billion Deal
The Japanese pharmaceutical company Takeda is buying Cambridge, Massachussets-based Ariad Pharmaceuticals for $24 a share. The deal is valued at about $5.2 billion and expected to close in February...
Related Articles
- Germany's Corporate Governance Problem also categorized in BoardNews
- Forbes Thinks Bill Ackman Might be the Next Warren Buffett also written by Portia Crowe
- Goldman Sachs CEO Lloyd Blankfein has Lymphoma also written by Portia Crowe
- GMI Ratings Governance Issue | Northrop Grumman Corp. also published in Business Insider
- GMI Ratings Update | Duke Energy Corporation also published in Business Insider
- Activist Investors are Really Polite in Japan also written by Portia Crowe
- Taiwan Court Orders Reinstatement Of Two CPDC Board Candidates As Contested Vote Nears also categorized in BoardNews
- CEOs Love Share Buybacks for the Most Obvious Reason in The World also written by Portia Crowe
- Barclays Has a New CEO and Big Changes Could be Coming also written by Portia Crowe
- Now Deutsche Bank is Freezing Executive Bonuses also written by Portia Crowe
Login to comment.